Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.

IF 1.8 4区医学 Q3 ONCOLOGY

Oncology-New York Pub Date : 2015-12-01

Graeme J Koelwyn, Erik Wennerberg, Sandra Demaria, Lee W Jones

引用次数: 0

Abstract

Pharmacologic manipulation of the immune system is emerging as a viable and robust treatment for some cancer patients. Exercise-induced modulation of the immune system may be another adjunctive strategy for inhibiting tumor initiation and progression. In healthy individuals, exercise has been shown to modulate a number of cell subsets involved in innate and adaptive immunity. Here, we provide an overview of the current state of knowledge pertaining to exercise modulation of the inflammation-immune axis in cancer. The current evidence suggests that exercise may be a promising adjunctive strategy that can favorably alter numerous components of the immune system, which, in turn, may modulate tumorigenesis. However, many important knowledge gaps are evident. To this end, we propose a framework to guide future research efforts investigating the immune effects of exercise in cancer.

本刊更多论文

运动在癌症发生和发展过程中对炎症-免疫轴功能的调节作用

对免疫系统的药物治疗正在成为一些癌症患者可行且有效的治疗方法。运动诱导的免疫系统调节可能是抑制肿瘤发生和发展的另一种辅助策略。在健康人中，运动已被证明能调节参与先天性免疫和适应性免疫的一些细胞亚群。在此，我们将概述目前有关运动调节癌症炎症-免疫轴的知识。目前的证据表明，运动可能是一种很有前景的辅助策略，它能有利地改变免疫系统的多种成分，进而调节肿瘤的发生。然而，许多重要的知识缺口是显而易见的。为此，我们提出了一个框架，以指导今后调查运动对癌症免疫效应的研究工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.